Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form

[Disclosure] Hanwha Systems (272210) – Announces Q1 2024 Provisional Consolidated Operating Profit of KRW 39.3B (+218.13% YoY)

Posted on April 26, 2024July 22, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Systems (272210) – Announces Q1 2024 Provisional Consolidated Operating Profit of KRW 39.3B (+218.13% YoY)

Fact Source: Financial Supervisory Service DART / 2024-04-26

Disclosure Type: Provisional Operating Performance (Consolidated Financial Statements) (Fair Disclosure)

💡 3-Second Summary

For Q1 2024, Hanwha Systems reported provisional consolidated revenue of KRW 544.4B (+23.86% YoY) and operating profit of KRW 39.3B (+218.13% YoY).

📊 1. [Key Disclosure Details & Financial Figures]

  • Reporting Category: Q1 2024 Consolidated Provisional Operating Performance (Unaudited internal settlement data)
  • Revenue:
    • Q1 2024: KRW 544,364,000,000 (Approx. KRW 544.4B)
    • QoQ Change (vs. Q4 2023 KRW 782.1B): -30.40%
    • YoY Change (vs. Q1 2023 KRW 439.5B): +23.86%
  • Operating Profit:
    • Q1 2024: KRW 39,264,000,000 (Approx. KRW 39.3B)
    • QoQ Change (vs. Q4 2023 KRW 11.0B): +258.06%
    • YoY Change (vs. Q1 2023 KRW 12.3B): +218.13%
  • Net Profit:
    • Q1 2024: KRW 50,323,000,000 (Approx. KRW 50.3B)
    • QoQ Change (vs. Q4 2023 KRW 42.2B): +19.12%
    • YoY Change (vs. Q1 2023 KRW 184.9B): -72.79%
  • Net Profit Attributable to Owners of the Parent:
    • Q1 2024: KRW 51,805,000,000 (Approx. KRW 51.8B)
    • QoQ Change: +18.55% / YoY Change: -72.20%
  • Profit Before Income Tax Expense from Continuing Operations:
    • Q1 2024: KRW 60,841,000,000 (Approx. KRW 60.8B)
    • QoQ Change: +229.73% / YoY Change: -73.36%
  • Other Notes:
    • The disclosure does not state specific reasons for the performance changes.
    • Data consists of internal settlement figures prior to external audit and is subject to change.
    • Related materials are scheduled to be posted on the company website (https://www.hanwhasystems.com).

📈 2. [Expert View: What This Disclosure Means for Investors]

This filing presents Hanwha Systems’ provisional consolidated financial results for the first quarter of 2024.

According to the figures, Q1 revenue and operating profit increased by 23.86% and 218.13% YoY, respectively. Conversely, net profit decreased by 72.79% YoY to KRW 50.3B compared to KRW 184.9B in Q1 2023. Compared to Q4 2023, revenue fell 30.40% while operating profit grew 258.06%. The filing does not provide specific drivers or causes explaining these financial changes. Furthermore, as these are unaudited internal settlement figures, final figures may be subject to adjustment following the external audit.

📝 Editor’s Comment (by K-STOCK Editor)

When reviewing provisional earnings disclosures, investors should evaluate both year-over-year (YoY) and quarter-over-quarter (QoQ) rate changes across key financial line items while noting that the data remains unaudited. In Q1 2024, revenue and operating profit expanded year-over-year, whereas net profit declined relative to the prior-year period.

Since the filing explicitly omits operational drivers for these financial changes, investors should note that these figures are provisional internal estimates subject to external audit results. Additionally, as specified in the disclosure, related presentation materials are scheduled to be posted on the official company website.

📢 Disclaimer & Source Notice

Source: This content was structured and newly generated based on official filing data from the Financial Supervisory Service’s DART system.

Investment Risk Warning: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Hanwha Systems (272210) – Announces Investor Relations (IR) Event for Q1 2024 Earnings for Major Domestic Institutional Investors
Next Post: [Disclosure] Samsung Biologics (207940) – (Correction) Major Management Matters Related to Investment Decisions / 2024-04-29

Related Posts

[Disclosure] Celltrion (068270) – CHMP Recommendation for Marketing Authorization for CT-P47 (RoActemra Biosimilar) / 2024-12-16 Disclosures
[Disclosure] Celltrion (068270) – Decision on Acquisition of Shares and Equity Securities of Other Corporation / 2025-09-23 Disclosures
[Disclosure] Hanwha Systems (272210) Signs KRW 1.2T Supply Contract with LIG Nex1 for ‘SA-MSAM Project Multifunction Radar Mass Production’ (Cheongung-II MFR Export to Saudi Arabia) Disclosures
[Disclosure] Jusung Engineering (036930) – Investment Notice on Stock Futures and Options (Re-notice on Scheduled Market Actions for Stock Futures Due to Corporate Spin-off Decision) / 2024-09-27 Semiconductors
[Disclosure] Hanwha Aerospace (012450) Signs KRW 473.1B Supply Contract with KAI for 17 Types of Initial Mass Production Components for KF-21 Disclosures
[Disclosure] Celltrion (068270) – Provisional Sales Results (Consolidated Financial Statements) / 2024-08-07 Bio & Healthcare

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hanwha Ocean (042660) – Clarification on Rumors or Reports (Unconfirmed) / 2026-08-07August 7, 2026
  • [Disclosure] ALTEOGEN (196170) – Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4 / 2026-08-05August 5, 2026
  • [Disclosure] ALTEOGEN (196170) – Ex-Rights (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] ALTEOGEN (196170) – Market Measures on Stock Futures and Options (Bonus Issue) / 2026-08-04August 4, 2026
  • [Disclosure] Celltrion (068270) – CT-P44 (Darzalex Biosimilar) Korea Phase 3 Clinical Trial Plan Amendment Application / 2026-08-03August 3, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme